Perspectives

What happens to medical innovation when policies undervalue medicines?

Why do new medicines reach patients faster in the United States?

HRSA finds 340B covered entity purchases have eclipsed $100 billion

How should drug prices be specified in U.S. economic analyses?

How have new medicines improved health and life expectancy in the United States?

Blog: The value of medicines in the U.S.

Who’s driving the surge in the 340B Program?

Perspective matters: The importance of understanding lived experience in considering the value of treatment

Minnesota finds large hospital systems collect most 340B profits, while middlemen siphon off tens of millions

J&J study in Nature journal reveals scale of investment in medical innovation, with the U.S. as a global launch pad